Drug Database
Back to search

United States· US:71904-200_378efc18-b873-47fa-b558-5ea92904a165

POMBILITI

A cipaglucosidase alfa product containing cipaglucosidase alfa, registered in United States by AMICUS THERAPEUTICS US, LLC. The same ATC class is registered in 13 of our 19 countries.

ATC A16AB23US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedPOMBILITIATCA16AB23REGISTER NO.US:71904-200_378efc18…PACKS LISTED6CHECKEDJuly 19, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cipaglucosidase alfaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cipaglucosidase alfa is registered in 13 of 19 countries.

Countries holding a registration under ATC A16AB23 (cipaglucosidase alfa), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose
Search cipaglucosidase alfa products by name

Cipaglucosidase alfa · ATC A16AB23

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cipaglucosidase alfa costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Cipaglucosidase alfa · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1264.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
CIPAGLUCOSIDASE ALFA
Manufacturer
AMICUS THERAPEUTICS US, LLC
Country
United States (US)
ATC code
A16AB23
ATC class
Cipaglucosidase alfa
Defined daily dose
0.1 g, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 19, 2026

Packs & prices · 6

  • ndc11
    71904-200-01
  • ndc11
    71904-200-02
  • ndc11
    71904-200-03
  • ndc11
    7190420001
    1 VIAL, GLASS in 1 CARTON (71904-200-01) / 105 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS
  • ndc11
    7190420002
    10 VIAL, GLASS in 1 CARTON (71904-200-02) / 105 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS
  • ndc11
    7190420003
    25 VIAL, GLASS in 1 CARTON (71904-200-03) / 105 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Cipaglucosidase alfa in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cipaglucosidase alfa products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Pombiliti
  • Liechtenstein · Pombiliti
  • Norway · Pombiliti

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/da848e00-ab21-46f3-a02a-59a86b449aee
GET /v1/drugs/da848e00-ab21-46f3-a02a-59a86b449aee?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "INTRAVENOUS",
  "source": "ndc",
  "strength": "105",
  "substance": "CIPAGLUCOSIDASE ALFA",
  "productndc": "71904-200",
  "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "BLA761204",
  "marketing_category": "BLA"
}
API referenceMCP serverPlans

See everything about cipaglucosidase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console